Inflammation, Weight Gain, and Metabolic Syndrome

A 52-year-old construction superintendent comes in for a weight conversation. He has gained 35 pounds since his late 30s, mostly in the abdomen. Blood pressure 142/88 on his last work physical. Fasting glucose 108. Triglycerides 220, HDL 32. His doctor told him to "watch his diet." His hs-CRP is 5.8, ferritin is 380 in the absence of iron overload risk factors, fasting insulin is 22, and his free testosterone is 240 ng/dL. He is not just overweight. He is in metabolic syndrome with active systemic inflammation, and the inflammation is both a consequence of and a driver of the rest of the picture. Telling him to watch his diet without addressing the inflammatory loop is a prescription that will not work.

I see this picture in patients from across middle Georgia — Columbus, Warner Robins, Fort Benning families, the line workers and superintendents and small-business owners who have been doing physical work their whole adult lives and watched their metabolism slow down anyway. The mechanism is the same regardless of the patient. The inflammation is the connective tissue between weight gain and metabolic disease, and once you can see the loop, the treatment plan changes.

What metabolic syndrome actually is — and why inflammation is the engine

Metabolic syndrome is a cluster diagnosis: any three of central adiposity (waist >40 inches in men, >35 in women), elevated fasting glucose (>100), elevated blood pressure (>130/85), elevated triglycerides (>150), and low HDL (<40 men, <50 women). The diagnosis was created because patients with this cluster have substantially higher risk of cardiovascular disease and type 2 diabetes than patients with any one of the components alone.

The cluster does not arise by coincidence. The unifying mechanism is insulin resistance plus chronic low-grade systemic inflammation, and the two reinforce each other in a feedback loop that is difficult to break with diet and exercise alone once it is fully established.

The mechanism, as I track it in patients:

1. Visceral fat expansion triggers a shift in adipose tissue secretion. Adiponectin (anti-inflammatory, insulin-sensitizing) drops. TNF-alpha, IL-6, leptin, and resistin rise.
2. TNF-alpha and IL-6 in circulation stimulate the liver to produce more C-reactive protein (CRP), more fibrinogen, more PAI-1, and more triglyceride-rich VLDL particles. This is what shows up as elevated hs-CRP, elevated triglycerides, and a thrombotic profile.
3. The same inflammatory cytokines impair insulin signaling at the muscle and liver receptor level — they phosphorylate IRS-1 in a way that blocks downstream glucose uptake. This is the molecular basis of insulin resistance in obesity.
4. Insulin resistance forces the pancreas to oversecrete insulin to maintain glucose control. High circulating insulin further promotes fat storage, suppresses fat oxidation, and drives more visceral expansion.
5. More visceral expansion produces more inflammatory cytokines. The loop is closed.

This is the engine. It runs autonomously once it is started, and it explains why the patient who genuinely cuts calories often does not lose weight — the metabolic environment is rigged against fat oxidation, and willpower does not change the cytokine profile.

The labs that actually show this picture

When I evaluate someone for medical weight loss, the panel is structured to find the inflammatory loop, not just confirm the BMI. The markers that matter:

• hs-CRP — high-sensitivity C-reactive protein. The most useful single inflammatory marker. Above 3 in someone without acute illness or autoimmune disease is metabolically significant. Above 5 in a patient with central adiposity is the loop running at high gear.
• Fasting insulin — the canary in the metabolic coal mine. Optimal under 7. Above 10 is insulin resistance regardless of glucose. Above 15 is severe.
• HOMA-IR calculated from fasting insulin and glucose — gives a single number for insulin resistance.
• HbA1c — three-month glucose average. Catches what fasting glucose misses.
• Triglyceride-to-HDL ratio — a triglyceride/HDL above 3.5 is highly suggestive of insulin resistance and small-dense LDL particle pattern.
• Ferritin — elevated ferritin in the absence of iron overload risk factors is often an inflammation marker.
• Full thyroid panel — TSH, free T3, free T4, reverse T3. Chronic inflammation impairs T4-to-T3 conversion and drives reverse T3 production. Many patients in this picture have suboptimal free T3 with normal TSH, which conventional screening misses.
• Sex hormone panel — declining testosterone in men and the perimenopausal estrogen-progesterone shift in women both worsen the inflammatory picture.
• Cortisol pattern — chronic stress elevates cortisol, which directly promotes visceral fat and worsens insulin resistance.
• Body composition — DEXA when available, waist circumference at minimum.

The lab review visit is where the plan gets built from this data. By then you have the same numbers I do, and the conversation is concrete.

Why "anti-inflammatory diet" alone usually underperforms

Patients arrive having tried various anti-inflammatory eating patterns — Mediterranean, paleo, AIP, gluten-free, sugar elimination. Some of these are legitimately useful. Most do not produce sustained weight loss as monotherapy in patients with established metabolic syndrome, and the reason is that the inflammatory loop has multiple inputs. Diet is one. The others — visceral fat mass itself, sleep architecture, cortisol pattern, sex hormone status, gut barrier integrity, environmental load — also matter, and none of them respond to diet changes alone in the timeframe most patients are willing to wait.

The most evidence-supported nutritional interventions for metabolic syndrome are the ones that reduce postprandial glucose excursions and reduce visceral fat: protein-forward meal composition (prioritizing 30-40 g protein per meal), strategic carbohydrate timing around resistance training, elimination of liquid sugars, and adequate fiber. I work through this individually with patients in nutritional counseling, because the right plan depends on what someone is currently eating, what they will actually sustain, and what their lab picture shows.

But nutrition is one lever. For patients in fully established metabolic syndrome, it usually has to be combined with other interventions — weight reduction at sufficient magnitude to reduce visceral mass, hormone optimization where the labs warrant, sleep correction, and pharmacologic support when indicated.

Where GLP-1 fits and where it does not

GLP-1 therapy directly targets several nodes in the loop. It improves insulin sensitivity, reduces hepatic glucose output, slows gastric emptying, suppresses appetite at the hypothalamic level, and — through weight loss itself — reduces visceral fat mass, which then improves the adipokine profile, which then reduces systemic inflammation. The downstream effect on hs-CRP in study populations is measurable: GLP-1-induced weight loss reliably reduces hs-CRP, often into normal range within 6-12 months.

This is why GLP-1 is appropriate for a meaningful percentage of patients with metabolic syndrome, even when they do not yet meet criteria for type 2 diabetes. The picture I look for: insulin resistance, central adiposity, elevated inflammatory markers, and at least one adjacent factor (suboptimal hormones, poor sleep, suboptimal thyroid). When that picture is present, GLP-1 within a structured program addressing the adjacent factors usually works.

It is not appropriate for everyone. The patient with already-low BMI, athletic body composition, or specific contraindications (personal or family history of medullary thyroid carcinoma, MEN2, prior pancreatitis) is not a candidate. And GLP-1 alone — without addressing the hormone picture, the sleep picture, the cortisol picture — predictably plateaus and regains.

How I evaluate someone in this picture

The first consultation is comprehensive. What I am working through:

The full inflammatory and metabolic panel described above, ordered at the first visit if recent results are not available.

Sleep history. Sleep apnea is dramatically underdiagnosed in patients with central adiposity and metabolic syndrome. A patient who snores, who has witnessed apneas, who wakes unrefreshed, who has a thick neck, or who has resistant hypertension needs a sleep study. Untreated sleep apnea will undermine every other intervention because it sustains the cortisol and inflammatory load.

Stress and cortisol pattern. Chronic stress is not an abstract problem in this picture. It is a measurable driver of visceral fat and insulin resistance.

Sex hormone picture. Mid-life weight gain is rarely separable from sex hormone status. Hormone optimization often has to run in parallel with weight loss intervention rather than after it.

Cardiovascular risk stratification. This is where 17 years in emergency medicine and the cardiac ICU shows up. Patients with metabolic syndrome are walking around with substantially elevated MI and stroke risk. I want to know lipid particle size, apoB, Lp(a), and family history before we are talking about weight as a number on a scale rather than a marker of cardiometabolic risk.

The concrete next step

If your waist is over the metabolic syndrome threshold, your blood pressure has crept up, your fasting glucose is in the 100-125 range, and you have been told to "watch your diet" without anyone running an hs-CRP or a fasting insulin, the next useful step is the panel. Specifically: hs-CRP, fasting insulin, HbA1c, triglyceride-to-HDL ratio, full thyroid, sex hormones, and a waist measurement. From those numbers a real plan can be built. Bring whatever prior labs you have, including any cardiac workup. The five-minute weight loss assessment will tell you whether the pattern fits before you book. To get scheduled, online booking handles both the Columbus clinic and the Warner Robins clinic; the medical weight loss program protocol is identical at each.

*Information in this article is educational and does not constitute medical advice. Diagnosis of metabolic syndrome and any pharmacologic intervention require a complete clinical evaluation. Individual results vary.*

TW

Travis Woodley

MSN, RN, CRNP — Platinum Biote Provider — Founder, Revitalize

Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.

Book a ConsultationCall (762) 261-3880

About Travis →More articles →Rebuild Institute →